Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiologí

Hypertension is a common cardiovascular risk factor leading to heart failure (HF), coronary artery disease, stroke, peripheral artery disease and chronic renal insufficiency. Hypertensive heart disease can manifest as many cardiac arrhythmias, most commonly being atrial fibrillation (AF). Both supraventricular and ventricular arrhythmias may occur in hypertensive patients, especially in those with left ventricular hypertrophy (LVH) or HF. Also, some of the antihypertensive drugs commonly used to reduce blood pressure, such as thiazide diuretics, may result in electrolyte abnormalities (e.g. hypokalaemia, hypomagnesemia), further contributing to arrhythmias, whereas effective control of blood pressure may prevent the development of the arrhythmias such as AF. In recognizing this close relationship between hypertension and arrhythmias, the European Heart Rhythm Association (EHRA) and the European Society of Cardiology (ESC) Council on Hypertension convened a Task Force, with representation from the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE), with the remit to comprehensively review the available evidence to publish a joint consensus document on hypertension and cardiac arrhythmias, and to provide up-to-date consensus recommendations for use in clinical practice. The ultimate judgment regarding care of a particular patient must be made by the healthcare provider and the patient in light of all of the circumstances presented by that patient.

[1]  J. C. Christiansen,et al.  Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. , 2020, Annals of internal medicine.

[2]  P. Kirchhof,et al.  [2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS]. , 2016, Kardiologia polska.

[3]  F. Cosío,et al.  European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiologia (SOLAECE). , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[4]  G. Lip,et al.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[5]  G. Lip Atrial Fibrillation in Patients With Hypertension: Trajectories of Risk Factors in Yet Another Manifestation of Hypertensive Target Organ Damage. , 2016, HYPERTENSION.

[6]  D. Lane,et al.  Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores , 2016, Journal of thrombosis and haemostasis : JTH.

[7]  Hans Eiskjær,et al.  Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. , 2016, The New England journal of medicine.

[8]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[9]  B. Davis,et al.  Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on Conduction System Disease. , 2016, JAMA internal medicine.

[10]  R. Shi,et al.  Arterial Stiffness, Central Pulsatile Hemodynamic Load, and Orthostatic Hypotension , 2016, The Journal of Clinical Hypertension.

[11]  L. Fauchier,et al.  Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated? , 2016, Stroke.

[12]  B. Olshansky,et al.  Conventional management of inappropriate sinus tachycardia , 2016, Journal of Interventional Cardiac Electrophysiology.

[13]  A. Camm,et al.  Catheter ablation vs. antiarrhythmic drug therapy in patients with symptomatic atrioventricular nodal re-entrant tachycardia: a randomized, controlled trial , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[14]  G. Lip,et al.  Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA2DS2-VASc Score 1 in Men, 2 in Women) Be Anticoagulated?: Yes Even 1 Stroke Risk Factor Confers a Real Risk of Stroke , 2016, Circulation.

[15]  Hugh Calkins,et al.  2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2016, Circulation.

[16]  Hugh Calkins,et al.  2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2016, Heart rhythm.

[17]  S. Anderson,et al.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.

[18]  D. Gladstone,et al.  The Risk Stratification and Stroke Prevention Therapy Care Gap in Canadian Atrial Fibrillation Patients. , 2016, The Canadian journal of cardiology.

[19]  G. Lip,et al.  Stroke prevention in atrial fibrillation and ‘real world’ adherence to guidelines in the Balkan Region: The BALKAN-AF Survey , 2016, Scientific Reports.

[20]  C. O’Seaghdha,et al.  Single Agent Antihypertensive Therapy and Orthostatic Blood Pressure Behaviour in Older Adults Using Beat-to-Beat Measurements: The Irish Longitudinal Study on Ageing , 2016, PloS one.

[21]  R. de Caterina,et al.  Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial , 2015, Journal of the American Heart Association.

[22]  F. Veglio,et al.  Cardiac Organ Damage and Arterial Stiffness in Autonomic Failure: Comparison With Essential Hypertension. , 2015, Hypertension.

[23]  G. de Simone,et al.  Cardiovascular ultrasound exploration contributes to predict incident atrial fibrillation in arterial hypertension: the Campania Salute Network. , 2015, International journal of cardiology.

[24]  S. Yusuf,et al.  Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial). , 2015, The American journal of cardiology.

[25]  S. Raj,et al.  Orthostatic hypotension: managing a difficult problem , 2015, Expert review of cardiovascular therapy.

[26]  Young-Soo Lee Atrial premature beats predict atrial fibrillation in cryptogenic stroke: results from the EMBRACE trial. , 2015 .

[27]  R. Mahajan,et al.  Impact of CARDIOrespiratory FITness on Arrhythmia Recurrence in Obese Individuals With Atrial Fibrillation: The CARDIO-FIT Study. , 2015, Journal of the American College of Cardiology.

[28]  G. Lip,et al.  Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation , 2015, Stroke.

[29]  R. de Caterina,et al.  Orthostatic Hypotension: Epidemiology, Prognosis, and Treatment. , 2015, Journal of the American College of Cardiology.

[30]  O. Nielsen,et al.  Excessive Atrial Ectopy and Short Atrial Runs Increase the Risk of Stroke Beyond Incident Atrial Fibrillation. , 2015, Journal of the American College of Cardiology.

[31]  P. Low,et al.  Orthostatic Hypotension: Mechanisms, Causes, Management , 2015, Journal of clinical neurology.

[32]  R. Bai,et al.  HATCH score in the prediction of new-onset atrial fibrillation after catheter ablation of typical atrial flutter. , 2015, Heart rhythm.

[33]  A. Moss,et al.  Improving clinical practice guidelines for practicing cardiologists. , 2015, The American journal of cardiology.

[34]  O. Melander,et al.  Orthostatic Changes in Hemodynamics and Cardiovascular Biomarkers in Dysautonomic Patients , 2015, PloS one.

[35]  G. Lip,et al.  Heart failure in patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Pilot survey on Atrial Fibrillation , 2015, European journal of heart failure.

[36]  Xu-Jiao Chen,et al.  Uncontrolled hypertension and orthostatic hypotension in relation to standing balance in elderly hypertensive patients , 2015, Clinical interventions in aging.

[37]  J. Halperin,et al.  Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism: mechanistic links and clinical inferences. , 2015, Journal of the American College of Cardiology.

[38]  D. Capodanno,et al.  Ventricular arrhythmias in aortic valve stenosis before and after transcatheter aortic valve implantation. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[39]  M. Rosenqvist,et al.  Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study , 2015, Circulation.

[40]  G. Lip,et al.  Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. , 2015, Journal of the American College of Cardiology.

[41]  Frank Bogun,et al.  Effect of ablation of frequent premature ventricular complexes on left ventricular function in patients with nonischemic cardiomyopathy. , 2015, Heart rhythm.

[42]  David J. Gladstone,et al.  Atrial Premature Beats Predict Atrial Fibrillation in Cryptogenic Stroke: Results From the EMBRACE Trial , 2015, Stroke.

[43]  P. Deedwania,et al.  Resting heart rate: risk indicator and emerging risk factor in cardiovascular disease. , 2015, The American journal of medicine.

[44]  A. Oto,et al.  A Prospective DE‐MRI Study Evaluating the Role of TGF‐β1 in Left Atrial Fibrosis and Implications for Outcomes of Cryoballoon‐Based Catheter Ablation: New Insights into Primary Fibrotic Atriocardiomyopathy , 2015, Journal of cardiovascular electrophysiology.

[45]  T. Chao,et al.  Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? , 2015, Journal of the American College of Cardiology.

[46]  G. Lip,et al.  Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[47]  T. Grodzicki,et al.  Meta-analysis of left ventricular hypertrophy and sustained arrhythmias. , 2014, The American journal of cardiology.

[48]  John Sapp,et al.  EHRA/HRS/APHRS expert consensus on ventricular arrhythmias , 2014, Heart rhythm.

[49]  T. Potpara,et al.  Diving to the foot of an iceberg: The SEARCH for undiagnosed atrial fibrillation , 2014, Thrombosis and Haemostasis.

[50]  A. Capucci,et al.  Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events , 2014, Circulation.

[51]  D. Singer,et al.  Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry , 2014, Circulation.

[52]  B. Nordestgaard,et al.  Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. , 2014, European heart journal.

[53]  S. Tobe,et al.  Combining other antihypertensive drugs with β-blockers in hypertension: a focus on safety and tolerability. , 2014, The Canadian journal of cardiology.

[54]  N. Lowres,et al.  Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies , 2014, Thrombosis and Haemostasis.

[55]  A. Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[56]  P. Kirchhof,et al.  A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[57]  G. Lip,et al.  Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation , 2014, European heart journal.

[58]  I. Durand-zaleski,et al.  Incidence and cost of stroke and hemorrhage in patients diagnosed with atrial fibrillation in France. , 2014, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[59]  Mukul Sharma,et al.  Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation , 2013, Thrombosis and Haemostasis.

[60]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[61]  G. Lip,et al.  Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. , 2013, Chest.

[62]  G. Lip,et al.  A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. , 2013, International journal of cardiology.

[63]  G. Lip,et al.  Cost Effectiveness of Treatments for Stroke Prevention in Atrial Fibrillation: Focus on the Novel Oral Anticoagulants , 2013, PharmacoEconomics.

[64]  V. Roger,et al.  Temporal Relationship and Prognostic Significance of Atrial Fibrillation in Heart Failure Patients With Preserved Ejection Fraction: A Community-Based Study , 2013, Circulation.

[65]  Simon Stewart,et al.  Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. , 2013, International journal of cardiology.

[66]  K. Swedberg,et al.  Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. , 2013, European heart journal.

[67]  J. Barthélémy,et al.  Sympathetic overactivity due to sleep fragmentation is associated with elevated diurnal systolic blood pressure in healthy elderly subjects: the PROOF-SYNAPSE study. , 2013, European heart journal.

[68]  Jeroen J. Bax,et al.  2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2013, European heart journal.

[69]  P. Kirchhof,et al.  Health technology assessment in interventional electrophysiology and device therapy: a position paper of the European Heart Rhythm Association. , 2013, European heart journal.

[70]  Daniel E. Singer,et al.  A New Risk Scheme to Predict Ischemic Stroke and Other Thromboembolism in Atrial Fibrillation: The ATRIA Study Stroke Risk Score , 2013, Journal of the American Heart Association.

[71]  G. Lip,et al.  Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry , 2013, PloS one.

[72]  A. Uy‐Evanado,et al.  Electrocardiographic Predictors of Sudden Cardiac Death in Patients with Left Ventricular Hypertrophy , 2013, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[73]  Julie Redfern,et al.  Screening to identify unknown atrial fibrillation , 2013, Thrombosis and Haemostasis.

[74]  Prashanthan Sanders,et al.  Long‐term Outcomes of Catheter Ablation of Atrial Fibrillation: A Systematic Review and Meta‐analysis , 2013, Journal of the American Heart Association.

[75]  David D. McManus,et al.  Simple Risk Model Predicts Incidence of Atrial Fibrillation in a Racially and Geographically Diverse Population: the CHARGE‐AF Consortium , 2013, Journal of the American Heart Association.

[76]  E. Lo,et al.  Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies , 2013, The Lancet Neurology.

[77]  I. V. Van Gelder,et al.  Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. , 2013, JACC. Heart failure.

[78]  David C. Wheeler,et al.  Notice , 2012, Kidney International Supplements.

[79]  Gerhard Hindricks,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[80]  Kazuomi Kario,et al.  Visit-to-visit and ambulatory blood pressure variability as predictors of incident cardiovascular events in patients with hypertension. , 2012, American journal of hypertension.

[81]  Habib Gamra,et al.  Distribution and Risk Profile of Paroxysmal, Persistent, and Permanent Atrial Fibrillation in Routine Clinical Practice: Insight From the Real-Life Global Survey Evaluating Patients With Atrial Fibrillation International Registry , 2012, Circulation. Arrhythmia and electrophysiology.

[82]  G. Lip,et al.  Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation: A Report From the Swedish Atrial Fibrillation Cohort Study , 2012, Circulation.

[83]  G. Lip,et al.  A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation study. , 2012, Chest.

[84]  K. Liestøl,et al.  Upper Normal Blood Pressures Predict Incident Atrial Fibrillation in Healthy Middle-Aged Men: A 35-Year Follow-Up Study , 2012, Hypertension.

[85]  A. Capucci,et al.  Subclinical atrial fibrillation and the risk of stroke. , 2012, The New England journal of medicine.

[86]  E. Dolan,et al.  Improved Late Survival and Disability After Stroke With Therapeutic Anticoagulation for Atrial Fibrillation: A Population Study , 2011, Stroke.

[87]  J. Tolstrup,et al.  Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study , 2011, Thrombosis and Haemostasis.

[88]  D. Singer,et al.  A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. , 2011, Journal of the American College of Cardiology.

[89]  G. Lip,et al.  Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[90]  Hidayet Kayançiçek,et al.  Assessment of atrial conduction time in patients with essential hypertension. , 2011, Journal of electrocardiology.

[91]  R. Vasan,et al.  Epidemiology and clinical course of heart failure with preserved ejection fraction , 2011, European journal of heart failure.

[92]  D. Singer,et al.  Moving the Tipping Point: The Decision to Anticoagulate Patients With Atrial Fibrillation , 2011, Circulation. Cardiovascular quality and outcomes.

[93]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[94]  G. Boriani,et al.  Role of drugs and devices in patients at risk of sudden cardiac death , 2010, Fundamental & clinical pharmacology.

[95]  O. Osadchii Mechanisms of hypokalemia‐induced ventricular arrhythmogenicity , 2010, Fundamental & clinical pharmacology.

[96]  V. Pyrgakis,et al.  Evaluation of left ventricular hypertrophy in patients requiring permanent pacing , 2010, Therapeutic advances in cardiovascular disease.

[97]  Frank Bogun,et al.  Relationship between burden of premature ventricular complexes and left ventricular function. , 2010, Heart rhythm.

[98]  K. Nagata,et al.  Blood Pressure Levels and Bleeding Events During Antithrombotic Therapy: The Bleeding With Antithrombotic Therapy (BAT) Study , 2010, Stroke.

[99]  L. Køber,et al.  Excessive Supraventricular Ectopic Activity and Increased Risk of Atrial Fibrillation and Stroke , 2010, Circulation.

[100]  Robby Nieuwlaat,et al.  Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. , 2010, Journal of the American College of Cardiology.

[101]  B. Howard,et al.  Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study , 2010, Journal of hypertension.

[102]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[103]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[104]  Daniel P. Morin,et al.  QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study. , 2009, European heart journal.

[105]  D. Liao,et al.  Abstract 1328: Premature Cardiac Contractions and Risk of Incident Ischemic Stroke , 2009 .

[106]  L. Thijs,et al.  Regression of Left Ventricular Mass by Antihypertensive Treatment: A Meta-Analysis of Randomized Comparative Studies , 2009, Hypertension.

[107]  K. Fukuda,et al.  Cardiac Innervation and Sudden Cardiac Death , 2009, Current cardiology reviews.

[108]  M. Law,et al.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies , 2009, BMJ : British Medical Journal.

[109]  C. Albert,et al.  Influence of Systolic and Diastolic Blood Pressure on the Risk of Incident Atrial Fibrillation in Women , 2009, Circulation.

[110]  D. Levy,et al.  Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study , 2009, The Lancet.

[111]  H. Crijns,et al.  Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. , 2008, JAMA.

[112]  T. Lumley,et al.  Blood pressure control and risk of incident atrial fibrillation. , 2008, American journal of hypertension.

[113]  R. Ferrari,et al.  Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial , 2008, The Lancet.

[114]  Adelaide M. Arruda-Olson,et al.  Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Coun , 2008, Journal of the American College of Cardiology.

[115]  M. Nieminen,et al.  Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study , 2008, Journal of hypertension.

[116]  Harlan M Krumholz,et al.  ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemaker , 2008, Journal of the American College of Cardiology.

[117]  Marmar Vaseghi,et al.  The role of the autonomic nervous system in sudden cardiac death. , 2008, Progress in cardiovascular diseases.

[118]  H. Tse,et al.  Hypertension and cardiac arrhythmias: a review of the epidemiology, pathophysiology and clinical implications , 2008, Journal of Human Hypertension.

[119]  T. Ogihara,et al.  Effects of Candesartan Compared With Amlodipine in Hypertensive Patients With High Cardiovascular Risks: Candesartan Antihypertensive Survival Evaluation in Japan Trial , 2008, Hypertension.

[120]  G. Lip,et al.  Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data , 2008, Thrombosis and Haemostasis.

[121]  C. Pepine,et al.  Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). , 2007, European heart journal.

[122]  G. Lip,et al.  Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. , 2007, QJM : monthly journal of the Association of Physicians.

[123]  Jean-Claude Tardif,et al.  Resting heart rate in cardiovascular disease. , 2007, Journal of the American College of Cardiology.

[124]  M. Nieminen,et al.  Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Therapy and Reduction in Sudden Cardiac Death: The LIFE Study , 2007, Circulation.

[125]  Independent predictors of stroke in patients with atrial fibrillation , 2007, Neurology.

[126]  D. Singer,et al.  Death and disability from warfarin-associated intracranial and extracranial hemorrhages. , 2007, The American journal of medicine.

[127]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[128]  G. Lip,et al.  Effect of hypertension on anticoagulated patients with atrial fibrillation. , 2007, European heart journal.

[129]  S. Willich,et al.  The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[130]  H. Crijns,et al.  Enhanced cardiovascular morbidity and mortality during rhythm control treatment in persistent atrial fibrillation in hypertensives: data of the RACE study. , 2007, European heart journal.

[131]  M. Rich,et al.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). , 2006, American heart journal.

[132]  R. Tieleman,et al.  Atrial extrasystoles after exercise predict atrial fibrillation in patients with left ventricular hypertrophy , 2005, Heart.

[133]  T. Kahan,et al.  Left ventricular hypertrophy in hypertension: its arrhythmogenic potential , 2005, Heart.

[134]  I. V. Van Gelder,et al.  Rate control in atrial fibrillation. , 2004, Journal of the American College of Cardiology.

[135]  Lauri Toivonen,et al.  QRS Duration and QT Interval Predict Mortality in Hypertensive Patients With Left Ventricular Hypertrophy: The Losartan Intervention for Endpoint Reduction in Hypertension Study , 2004, Hypertension.

[136]  S. Priori,et al.  ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing co , 2003, Journal of the American College of Cardiology.

[137]  W. DuMouchel,et al.  Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post‐marketing setting , 2003, Pharmacoepidemiology and drug safety.

[138]  A. Waldo Stroke prevention in atrial fibrillation. , 2003, JAMA.

[139]  K. Borch-Johnsen,et al.  Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study , 2003, The Lancet.

[140]  W. Elliott,et al.  The Economic Impact of Hypertension , 2003, Journal of clinical hypertension.

[141]  Maurizio Bentivoglio,et al.  Atrial Fibrillation in Hypertension: Predictors and Outcome , 2003, Hypertension.

[142]  T. Kahan,et al.  Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA). , 2002, The American journal of cardiology.

[143]  S. Mochizuki,et al.  Hypertension‐Related Intermyocyte Junction Remodelling is Associated with a Higher Incidence of Low‐K+‐Induced Lethal Arrhythmias in Isolated Rat Heart , 2002, Experimental physiology.

[144]  M. Rich,et al.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. , 2001, JAMA.

[145]  S. Borzak,et al.  Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence. , 2001, Progress in cardiovascular diseases.

[146]  P Lavie,et al.  Obstructive Sleep Apnea and Hypertension: From Correlative to Causative Relationship , 2001, Journal of clinical hypertension.

[147]  M. Barbagallo,et al.  Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH. , 2001, American journal of hypertension.

[148]  A. Oksenberg,et al.  Are sleep-related breathing disorders important contributing factors to the production of essential hypertension? , 2001, Current hypertension reports.

[149]  S. Hohnloser,et al.  Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial , 2000, The Lancet.

[150]  K. Umetani,et al.  Cardiac arrhythmias and left ventricular hypertrophy in dipper and nondipper patients with essential hypertension. , 2000, Japanese circulation journal.

[151]  W. Kannel,et al.  Vital epidemiologic clues in heart failure. , 2000, Journal of clinical epidemiology.

[152]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[153]  F. Messerli Hypertension and sudden cardiac death. , 1999, American journal of hypertension.

[154]  A. Saadeh,et al.  QTc dispersion and complex ventricular arrhythmias in untreated newly presenting hypertensive patients , 1999, Journal of Human Hypertension.

[155]  D. Levy,et al.  Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. , 1998, Journal of the American College of Cardiology.

[156]  P A Wolf,et al.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. , 1998, The American journal of cardiology.

[157]  H. Gavras,et al.  Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy: effects on LVH regression and arrhythmogenic propensity. , 1998, American journal of hypertension.

[158]  S. Boveda,et al.  Prognostic value of ventricular arrhythmias in systemic hypertension , 1997, Journal of hypertension.

[159]  M. Barbagallo,et al.  Increased prevalence of cardiac arrhythmias and transient episodes of myocardial ischemia in hypertensives with left ventricular hypertrophy but without clinical history of coronary heart disease. , 1997, American journal of hypertension.

[160]  S. Thom,et al.  The effects on cardiac arrhythmias of antihypertensive therapy causing regression of left ventricular hypertrophy. , 1997, American Journal of Hypertension.

[161]  R. Ajisaka,et al.  Alterations in left ventricular wall stress and coronary circulation in patients with isolated systolic hypertension , 1996, Journal of hypertension.

[162]  T. Raghunathan,et al.  Diuretic therapy for hypertension and the risk of primary cardiac arrest. , 1994, The New England journal of medicine.

[163]  D. Sideris High blood pressure and ventricular arrhythmias. , 1993, European heart journal.

[164]  S. Hohnloser,et al.  Prevalence of Circadian Variations and Spontaneous Variabilit of Cardiac Disorders and ECG Changes Suggestive of Myocardial Ischemia in Systemic Arterial Hypertension , 1992, Circulation.

[165]  P. Macfarlane,et al.  Significance of ventricular arrhythmias in systemic hypertension with left ventricular hypertrophy. , 1992, The American journal of cardiology.

[166]  S B Hulley,et al.  Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men. , 1992, JAMA.

[167]  H. Calkins,et al.  Effect of acute volume load on refractoriness and arrhythmia development in isolated, chronically infarcted canine hearts. , 1989, Circulation.

[168]  N. Kaplan Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. , 1988 .

[169]  D. Levy,et al.  Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. , 1987, The American journal of cardiology.

[170]  R. Kleiger,et al.  Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. , 1986, The New England journal of medicine.

[171]  W. Kannel,et al.  Sudden death: lessons from subsets in population studies. , 1985, Journal of the American College of Cardiology.

[172]  E. Bixler,et al.  SLEEP APNOEA IN A HYPERTENSIVE POPULATION , 1984, The Lancet.

[173]  S. Kawai,et al.  Histopathology of the conduction system in sudden cardiac death. , 1983, Japanese circulation journal.

[174]  U. Schotten,et al.  Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation , 2017, European heart journal.

[175]  F. Cosío,et al.  European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiologia (SOLAECE). , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[176]  Andrea Mazzanti,et al.  [2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death]. , 2015, Kardiologia polska.

[177]  P. Lantelme,et al.  Significance, prognostic value and management of heart rate in hypertension. , 2014, Archives of cardiovascular diseases.

[178]  Kyle W. Klarich,et al.  Premature Ventricular Contraction-Induced Cardiomyopathy: A Treatable Condition , 2012, Circulation. Arrhythmia and electrophysiology.

[179]  D. Xavier,et al.  Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .

[180]  Karly P Garnock-jones Esmolol , 2012, Drugs.

[181]  Elsayed Z Soliman,et al.  A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). , 2011, The American journal of cardiology.

[182]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[183]  M. Wright,et al.  Controversies in cardiovascular medicine Drugs vs . ablation for the treatment of atrial fibrillation : the evidence supporting catheter ablation , 2010 .

[184]  G. De Luca,et al.  "Meta-analysis of ablation of atrial flutter and supraventricular tachycardia". , 2010, The American journal of cardiology.

[185]  Claudia Stöllberger,et al.  Guidelines for device-based therapy of cardiac rhythm abnormalities. , 2009, Heart rhythm.

[186]  N. Tribulova,et al.  Adaptation of the heart to hypertension is associated with maladaptive gap junction connexin-43 remodeling. , 2008, Physiological research.

[187]  Jeroen J. Bax,et al.  2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Blood pressure.

[188]  D. Faxon,et al.  Guidelines for the Management of Patients With Supraventricular Arrhythmias * — Executive Summary , 2003 .

[189]  D. Faxon,et al.  Tomaselli Gf. Acc/aha/esc Guidelines for the Management of Patients with Supraventricular Arrhythmias: a Report of the American College of Cardiology/american Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing Committ , 2022 .

[190]  G. Heiss,et al.  Association of ventricular premature complexes with electrocardiographic-estimated left ventricular mass in a population of African-American and white men and women (The Atherosclerosis Risk in Communities. , 2001, The American journal of cardiology.

[191]  A. Kitsiou,et al.  The circadian profile of extrasystolic arrhythmia: its relationship to heart rate and blood pressure. , 1992, International journal of cardiology.

[192]  J. Lumme,et al.  Cardiac arrhythmias in hypertensive outpatients on various diuretics. Correlation between incidence and serum potassium and magnesium levels. , 1986, Annals of clinical research.

[193]  G. Lip,et al.  Factors Affecting Quality of Anticoagulation Control Among Patients With Atrial Fibrillation on Warfarin The SAMe-TT 2 R 2 Score , 2022 .

[194]  Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA 2 DS 2 -VASc score A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy , 2022 .